CN102000023B - Momestasone furoate cream and preparation method thereof - Google Patents

Momestasone furoate cream and preparation method thereof Download PDF

Info

Publication number
CN102000023B
CN102000023B CN2010105494071A CN201010549407A CN102000023B CN 102000023 B CN102000023 B CN 102000023B CN 2010105494071 A CN2010105494071 A CN 2010105494071A CN 201010549407 A CN201010549407 A CN 201010549407A CN 102000023 B CN102000023 B CN 102000023B
Authority
CN
China
Prior art keywords
parts
momestasone furoate
water
propylene glycol
emulsifiable paste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2010105494071A
Other languages
Chinese (zh)
Other versions
CN102000023A (en
Inventor
李军
吴泽榕
徐玉琴
曹员霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Resources Sanjiu Nanchang Pharmaceutical Co Ltd
Original Assignee
Jiangxi Sanjiu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Sanjiu Pharmaceutical Co Ltd filed Critical Jiangxi Sanjiu Pharmaceutical Co Ltd
Priority to CN2010105494071A priority Critical patent/CN102000023B/en
Publication of CN102000023A publication Critical patent/CN102000023A/en
Application granted granted Critical
Publication of CN102000023B publication Critical patent/CN102000023B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The invention relates to the technical field of an external preparation medicament, in particular to an external preparation medicament containing momestasone furoate. The external preparation medicament is prepared from the following raw materials in part by weight: 15 parts of the momestasone furoate, 45 parts of hexadecyl-octadecyl alcohol, 7.5 parts of glyceryl monostearate, 5 parts of beeswax, 8 parts of triethanolamine, 35 parts of light liquid paraffin, 2 parts of sodium lauryl sulfate, 8 parts of sodium lauryl sulfate, 25 parts of propylene glycol, 1 part of Hydroxy acetate, 2 parts of tween-80, and the balance of purified water which is added to ensure that the total weight is 500 parts. The cream has better moisture retention and stability because the humectant combination of the triethanolamine and the propylene glycol is adopted.

Description

Momestasone furoate emulsifiable paste and preparation method thereof
Technical field
The present invention relates to a kind of technical field of external preparation medicine, especially a kind of external preparation medicine that contains momestasone furoate, this emulsifiable paste are the wetting agent combinations of triethanolamine and propylene glycol owing to what adopt, have better moisture retention and stability.
Background technology
Momestasone furoate is the local glucocorticoid medicine of synthetic, has the low characteristics of cortex hormone function inhibition on the curative effect kidney tonifying.The momestasone furoate emulsifiable paste has the effect that reduces inflammation with pruritus, is applicable to effective dermatosis of glucocorticoid such as dermatitis (contact dermatitis, seborrheic dermatitis, atoipc dermatitis, neurodermatitis); Acute, subacute, chronic eczema, discoid lupus erythematosus; Lichen planus, skin amyloidosis lichen, granuloma annulare; The small size psoriasis, pretibial myxedema etc.
At present, the momestasone furoate emulsifiable paste of market sale, stability is generally relatively poor, and emulsifiable paste hardens easily behind the use opening, and product quality changes, the result of use poor response.What is more, has relevant report to point out that some momestasone furoate emulsifiable paste series of products also has certain side effect, like the hypercortisolisms that the inhibition of HAP axle, long-term a large amount of uses are caused; Cause thinning of skin like meeting; The skin surface telangiectasis, and can cause cutis laxa, bring out acne, cause hair follicle to infect, the hair undue growth; Skin allergy, and might cause physiological period disorder etc.
Therefore research and develop a moisture retention and stability is better, and the momestasone furoate cream products with low side effect has great importance.
The present invention is to provide the external preparation medicine that contains Momestasone furoate lipidosome, this emulsifiable paste is the wetting agent combination of triethanolamine and propylene glycol owing to what adopt, has better moisture retention and stability.The selection of wetting agent is added can better keep not dehydration of mastic, not atrophy, makes mastic keep stable before the deadline.This emulsifiable paste also has good heat-resisting cold tolerance simultaneously.
Summary of the invention
The purpose of this invention is to provide a kind of momestasone furoate emulsifiable paste, especially a kind of external preparation medicine that contains momestasone furoate, this emulsifiable paste are the wetting agent combinations of triethanolamine and propylene glycol owing to what adopt, thereby have better moisture retention and stability.
Momestasone furoate emulsifiable paste provided by the present invention is realized through following technical scheme:
The momestasone furoate emulsifiable paste; Processed by the following weight proportion raw material: 15 parts of momestasone furoates, 45 parts of hexadeca-octadecyl alcohols, 7.5 parts of single stearic acid glyceride, 5 parts in Cera Flava, 35 parts of light liquid petrolatums, 5 parts of sodium lauryl sulphates, 25 parts of propylene glycol, 1 part in hydroxyl second fat, the purified water ad pond om that adds surplus are 500 parts; Wherein: the method for preparing of momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 80-85 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate and stir and make dissolving, cross 150 mesh sieves, to 80-85 ℃ of insulation half an hour, subsequent use; 3, with momestasone furoate and low amounts of water and mixed with propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during, water is slowly poured in the oil phase, when being stirred to 50-55 ℃,, just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped momestasone furoate and low amounts of water and mixed with propylene glycol solution all at 75-80 ℃.
The momestasone furoate emulsifiable paste; Process by the following weight proportion raw material: 15 parts of momestasone furoates, 45 parts of hexadeca-octadecyl alcohols, 7.5 parts of single stearic acid glyceride, 5 parts in Cera Flava, 8 parts of triethanolamine, 35 parts of light liquid petrolatums, 2 parts of sodium lauryl sulphates; 8 parts of sodium laurylsulfates, 25 parts of propylene glycol, 1 part in hydroxyl second fat, 2 parts of tween 80s, the purified water ad pond om that adds surplus are 500 parts; Wherein: the method for preparing of momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 80-85 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate, sodium laurylsulfate and stir and make dissolving, cross 150 mesh sieves, be incubated half an hour to 80-85 ℃ with, tween 80, subsequent use; 3, momestasone furoate is mixed with triethanolamine with low amounts of water, propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during all at 75-80 ℃; Water is slowly poured in the oil phase, when being stirred to 50-55 ℃, momestasone furoate and low amounts of water, propylene glycol and triethanolamine mixed solution; Just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped.
The purpose of this invention is to provide a kind of momestasone furoate emulsifiable paste, its adjuvant is selected appropriate, can be so that momestasone furoate emulsifiable paste performance of keeping humidity is more outstanding.The present invention is except selecting wetting agent; Also added non-wetting agent sodium laurylsulfate in the raw material; But through the interpolation of sodium lauryl sulphate, sodium laurylsulfate, tween 80 in the evidence momestasone furoate emulsifiable paste raw material and the wetting agent combination of triethanolamine and propylene glycol; Make that the performance of keeping humidity of mastic is better, thereby momestasone furoate emulsifiable paste provided by the present invention has better moisture retention and stability.
Advantage of the present invention: the emulsifiable paste matrix made from stearic acid; The smooth in appearance exquisiteness is attractive in appearance; And be easy to be applied in skin, leave one deck stearic acid thin film after the water evaporates and have protectiveness, wherein the situation of stearic addition also needs to do suitably adjustment according to factors such as season, weathers; The interpolation of Cera Flava, light liquid petrolatum can better be regulated the denseness and increase gloss of mastic; Aqueous phase uses sodium lauryl sulphate as emulsifying agent, makes profit under certain condition biphase, can closely combine and make mastic to be shaped; Add triethanolamine and propylene glycol and make up as wetting agent, can well keep not dehydration of mastic, not atrophy makes mastic keep steady statue before the deadline.
The specific embodiment:
Every gram Eloson emulsifiable paste contains 0.1% momestasone furoate, and other non-active ingredient has white vaseline, white beeswax, stearic acid propyleneglycoles, titanium dioxide, water and phosphoric acid solution.
Embodiment 1, momestasone furoate emulsifiable paste; Processed by the following weight proportion raw material: 15 parts of momestasone furoates, 45 parts of hexadeca-octadecyl alcohols, 7.5 parts of single stearic acid glyceride, 5 parts in Cera Flava, 35 parts of light liquid petrolatums, 5 parts of sodium lauryl sulphates, 25 parts of propylene glycol, 1 part of ethyl hydroxybenzoate, the purified water ad pond om that adds surplus are 500 parts
Wherein: the method for preparing of momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 80-85 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate and stir and make dissolving, cross 150 mesh sieves, to 80-85 ℃ of insulation half an hour, subsequent use; 3, with momestasone furoate and low amounts of water and mixed with propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during, water is slowly poured in the oil phase, when being stirred to 50-55 ℃,, just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped momestasone furoate and low amounts of water and mixed with propylene glycol solution all at 75-80 ℃.
Embodiment 2, momestasone furoate emulsifiable paste; Processed by the following weight proportion raw material: 15 parts of momestasone furoates, 45 parts of hexadeca-octadecyl alcohols, 7.5 parts of single stearic acid glyceride, 5 parts in Cera Flava, 35 parts of light liquid petrolatums, 5 parts of sodium lauryl sulphates, 25 parts of propylene glycol, 1 part in hydroxyl second fat, the purified water ad pond om that adds surplus are 500 parts
Wherein: the method for preparing of momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 80-85 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate and stir and make dissolving, cross 150 mesh sieves, to 80-85 ℃ of insulation half an hour, subsequent use; 3, with momestasone furoate and low amounts of water and mixed with propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during, water is slowly poured in the oil phase, when being stirred to 50-55 ℃,, just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped momestasone furoate and low amounts of water and mixed with propylene glycol solution all at 75-80 ℃.
Embodiment 3, momestasone furoate emulsifiable paste; Processed by the following weight proportion raw material: 15 parts of momestasone furoates, 45 parts of hexadeca-octadecyl alcohols, 7.5 parts of single stearic acid glyceride, 5 parts in Cera Flava, 8 parts of triethanolamine, 35 parts of liquid paraffin,lights, 2 parts of sodium lauryl sulphates, 8 parts of sodium laurylsulfates, 25 parts of propylene glycol, 1 part in hydroxyl second fat, 2 parts of tween 80s, the purified water ad pond om that adds surplus are 500 parts.
Wherein: the method for preparing of momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 80-85 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate, sodium laurylsulfate and stir and make dissolving, cross 150 mesh sieves, be incubated half an hour to 80-85 ℃ with, tween 80, subsequent use; 3, momestasone furoate is mixed with triethanolamine with low amounts of water, propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during all at 75-80 ℃; Water is slowly poured in the oil phase, when being stirred to 50-55 ℃, momestasone furoate and low amounts of water, propylene glycol and triethanolamine mixed solution; Just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped.
The method for preparing of embodiment 3-1, momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 80 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate, sodium laurylsulfate and stir and make dissolving, cross 150 mesh sieves, be incubated half an hour to 80 ℃ with, tween 80, subsequent use; 3, momestasone furoate is mixed with triethanolamine with low amounts of water, propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during, water is slowly poured in the oil phase, when being stirred to 50 ℃,, just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped momestasone furoate and low amounts of water, propylene glycol and triethanolamine mixed solution all at 75 ℃.All the other are with embodiment 3.
The method for preparing of embodiment 3-2, momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 85 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate, sodium laurylsulfate and stir and make dissolving, cross 150 mesh sieves, be incubated half an hour to 85 ℃ with, tween 80, subsequent use; 3, momestasone furoate is mixed with triethanolamine with low amounts of water, propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during, water is slowly poured in the oil phase, when being stirred to 55 ℃,, just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped momestasone furoate and low amounts of water, propylene glycol and triethanolamine mixed solution all at 80 ℃.All the other are with embodiment 3.
The method for preparing of embodiment 3-3, momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 82 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate, sodium laurylsulfate and stir and make dissolving, cross 150 mesh sieves, be incubated half an hour to 82 ℃ with, tween 80, subsequent use; 3, momestasone furoate is mixed with triethanolamine with low amounts of water, propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during, water is slowly poured in the oil phase, when being stirred to 53 ℃,, just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped momestasone furoate and low amounts of water, propylene glycol and triethanolamine mixed solution all at 78 ℃.All the other are with embodiment 3.
Embodiment 4, momestasone furoate emulsifiable paste make the momestasone furoate emulsifiable paste by the momestasone furoate emulsifiable paste effect that makes of embodiment 1-3 with embodiment 3.
The momestasone furoate emulsifiable paste that is made by embodiment 1, embodiment 2, embodiment 3 is carried out moisture retention test, stability test embodiment and stability test.
The moisture retention test example
To be divided into three groups of A, B, C by the momestasone furoate emulsifiable paste that embodiment 1, embodiment 2, embodiment 3 make, other is provided with the 4th group of D (wherein the 4th group of sample that provides is by the common momestasone furoate emulsifiable paste that obtains on the market).
The moisture retention test example
Extracting waste glazed paper is cut into 1cm * 2cm, 2cm * 4cm, 3cm * 6cm size; Accurate heavy after, evenly be coated with last layer sample (the different size sheets of each sample are respectively done 2 parts), weigh, put into calorstat (25 ± 1) ℃ insulation 4h after; Taking-up is weighed, unit of account area water evaporates amount, and 4 groups of prescription water evaporates amounts are respectively (18.0 ± 2.3) as a result; (9.3 ± 1.4), (8.7 ± 1.3), (19.7 ± 1.2) mgcm -2
Stability test embodiment
1, accelerated test is investigated the result
We are according to " the requirement of accelerated test in Chinese pharmacopoeia two appendix of version in 2005 " medicine stability test guideline "; A, B, C, each 15g of D prescription substrate are contained in the emulsifiable paste box; Being positioned over temperature is 30 ± 2 ℃; Relative humidity is in 65 ± 5 ℃ the cupboard that keeps sample; In sampling in 1,2,3,4,5,6 month, in " medicine stability test guideline ", each item of pharmaceutical preparation stability high spot reviews project required these article have been carried out the investigation of character, content, uniformity, catabolite, granularity, lamination.
The result: through 30 ± 2 ℃ of temperature, relative humidity can find out obviously that 65 ± 5 ℃ environment held 6 months momestasone furoate emulsifiable paste each item index that embodiment 3 makes has no significant change.Conclusion: these article are 30 ± 2 ℃ of temperature, and relative humidity was 65 ± 5 ℃ environment held 6 months, and these article are stable.
2, the investigation result that keeps sample for a long time
We are according to " the requirement of Chinese pharmacopoeia two appendix of version in 2005 " medicine stability test guideline " long term test; A, B, C, each 15g of D prescription substrate are contained in the emulsifiable paste box; Being positioned over temperature is 25 ± 2 ℃; Relative humidity is in 60 ± 5 ℃ the cupboard that keeps sample; In sampling in 3,6 months, require these article have been carried out the investigation of character, content, uniformity, catabolite, granularity, lamination with each item of " medicine stability test guideline " Chinese medicine preparation stability high spot reviews project.
Figure BSA00000351238600052
Figure BSA00000351238600061
The result: kept sample for a long time 6 months, each item index was compared with 0 month, no significant change.The test that keeps sample for a long time is still underway.
Low temperature and hot constant temperature test embodiment
Get A, B, C, D prescription substrate 15g contains in the emulsifiable paste box, places refrigerator and the incubator of steady temperature respectively, under different temperatures, stores 24h, takes out, and after waiting to return back to room temperature, on microscope slide, is coated with skim, the observation lamination, the result is form as follows.
Figure BSA00000351238600062
Annotate: "-" no change, "+" chap, " // " layering
Conclusion (of pressure testing): embodiment result learns according to stability test: the momestasone furoate emulsifiable paste that is made by embodiment 3 has better temperature resistance, and is cold-resistant best with heat resistance, can under-10 ℃-40 ℃, maintain a relatively stable state; The result learns according to the moisture retention test example: the percentage of water loss of the momestasone furoate emulsifiable paste that is made by embodiment 3 is minimum, has better moisture retention.
Comprehensive above conclusion can know that the momestasone furoate emulsifiable paste that is made by embodiment 3 is best.

Claims (1)

1. momestasone furoate emulsifiable paste; Process by the following weight proportion raw material: 15 parts of momestasone furoates, 45 parts of hexadeca-octadecyl alcohols, 7.5 parts of single stearic acid glyceride, 5 parts in Cera Flava, 8 parts of triethanolamine, 35 parts of liquid paraffin,lights, 2 parts of sodium lauryl sulphates; 8 parts of sodium laurylsulfates, 25 parts of propylene glycol, 1 part in hydroxyl second fat, 2 parts of tween 80s, the purified water ad pond om that adds surplus are 500 parts
It is characterized in that: the method for preparing of momestasone furoate emulsifiable paste is: 1, oil phase: take by weighing recipe quantity required 16-18 mixed alcohols, glyceryl monostearate, Cera Flava, liquid paraffin,light, ethyl hydroxybenzoate Hybrid Heating and make fusion; To 80-85 ℃ the insulation half an hour after; Cross 150 mesh sieves, subsequent use; 2, water: take by weighing the required purified water of recipe quantity when being heated to 80 ℃ of left and right sides, add sodium lauryl sulphate, sodium laurylsulfate and stir with tween 80 and make dissolving, cross 150 mesh sieves, be incubated half an hour to 80-85 ℃, subsequent use; 3, momestasone furoate is mixed with triethanolamine with low amounts of water, propylene glycol, stir, make mixing, cross 150 mesh sieves, subsequent use; 4, when profit phase temperature during all at 75-80 ℃; Water is slowly poured in the oil phase, when being stirred to 50-55 ℃, momestasone furoate and low amounts of water, propylene glycol and triethanolamine mixed solution; Just slowly be added in emulsive emulsion, continue to stir and be cooled to mastic and be shaped.
CN2010105494071A 2010-11-18 2010-11-18 Momestasone furoate cream and preparation method thereof Active CN102000023B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010105494071A CN102000023B (en) 2010-11-18 2010-11-18 Momestasone furoate cream and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010105494071A CN102000023B (en) 2010-11-18 2010-11-18 Momestasone furoate cream and preparation method thereof

Publications (2)

Publication Number Publication Date
CN102000023A CN102000023A (en) 2011-04-06
CN102000023B true CN102000023B (en) 2012-05-30

Family

ID=43807892

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010105494071A Active CN102000023B (en) 2010-11-18 2010-11-18 Momestasone furoate cream and preparation method thereof

Country Status (1)

Country Link
CN (1) CN102000023B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106138066B (en) * 2015-04-02 2018-12-28 广州朗圣药业有限公司 A kind of Momestasone furoate cream and preparation method thereof
CN109512778A (en) * 2017-09-18 2019-03-26 江苏吉贝尔药业股份有限公司 A kind of cream and preparation method of Halometasone
CN112402366A (en) * 2020-11-12 2021-02-26 广州白云山医药集团股份有限公司白云山何济公制药厂 Mometasone furoate cream and preparation method thereof
CN113230203B (en) * 2021-05-18 2023-04-18 广州白云山医药集团股份有限公司白云山何济公制药厂 Mometasone furoate gel and preparation method thereof
CN113520993B (en) * 2021-07-30 2022-07-29 海南海神同洲制药有限公司 Preparation method of low-viscosity sertaconazole nitrate cream and product prepared by same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
CN101199855A (en) * 2006-12-13 2008-06-18 天津药业研究院有限公司 Skinniness hormone packing matter water solution and application thereof
CN101015559A (en) * 2007-02-06 2007-08-15 复旦大学 Instant gelling agent for treating allergic rhinitis

Also Published As

Publication number Publication date
CN102000023A (en) 2011-04-06

Similar Documents

Publication Publication Date Title
CN102000023B (en) Momestasone furoate cream and preparation method thereof
CN104814881B (en) A kind of moisturizing remediation composition and the epidermis Biomimetic membranes liquid crystal complex constructed by it
CN103494714B (en) A kind of emulsifier combination and application that can form liquid crystal structure
CN106389304A (en) Multi-effect mild moisturizer containing plant lactobacillus fermented rice
CN103202772A (en) Cream composition with stable liquid crystal structure and preparation method thereof
CN105411865A (en) Multi-effect moisturizing microemulsion essence containing multiple vegetable oil and fat
CN104069033B (en) Highly concentrated allantoin homogeneous premixed material series of products and preparation method thereof
CN104434720A (en) Spontaneous type temperature sensing mask and preparation method thereof
CN108743453A (en) A kind of compounding layered liquid crystal emulsifier and its application and the cosmetics with layered liquid crystal structure
CN106176321A (en) A kind of lipstick rich in moisture and preparation method thereof
CN103417404A (en) Exfoliating condensation and preparation method thereof
CN111888276B (en) Lip care composition containing phytosterol additive and preparation method thereof
CN102178240A (en) Method for preparing microemulsion of walnut oil
Sellner et al. Time course of changes in fatty acid composition of gills and liver from rainbow trout (Salmo gairdneri) during thermal acclimation
CN102319202B (en) Mometasone furoate gel and preparation method thereof
CN114848533A (en) Preparation method of nano-liposome efficiently-coated composite ceramide
CN109527120B (en) Food-grade bacteriostatic oil gel based on vegetable oil and rich in polyunsaturated fatty acid and preparation method thereof
Konings et al. Can the excretion of metabolites by bacteria be manipulated?
CN101926753A (en) Pearl powder ointment cream and preparation method thereof
JP5219344B2 (en) Topical skin preparation
CN106619216A (en) Essential oil microcapsule inclusion, as well as preparation method and application thereof
US10813969B2 (en) Artificial sebum film and method of producing same
CN101524316B (en) Acne-removing cream capable of rapidly removing facial acne without leaving marks on face
CN106727100A (en) A kind of anti-acne cream composition, acne eliminating cream and preparation method
CN110267642A (en) Oily composition, its preparation method, oiliness base and skin preparations for extenal use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: CHINA RESOURCES SANJIU (NANCHANG) PHARMACEUTICAL C

Free format text: FORMER NAME: JIANGXI SANJIU PHARMACEUTICAL INDUSTRY CO., LTD.

CP03 Change of name, title or address

Address after: 330012, Dongsheng Road, Chang Dong Industrial Zone, Jiangxi, Nanchang, 398

Patentee after: Huarun 39 (Nanchang) Pharmaceutical Co., Ltd.

Address before: 330012 No. two, No. 16, Chang Dong Road, Chang Dong Industrial Zone, Jiangxi, Nanchang

Patentee before: Jiangxi Sanjiu Pharmaceutical Co., Ltd.